

Forum diabetologicum 2013; 2

Regisler klíčových slov

klíčové slovo	(číslo): strany	klíčové slovo	(číslo): strany
akútne srdcové zlyhávanie	(1): 23–26	gliptíny	(2): 130–139
akútny koronárny syndróm	(1): 23–26	gravida	(3): 176–180
aliskirén	(1): 11–17		(3): 181–184
antiagregačná liečba	(2): 68–73	hypertriacylglycerolémie	(2): 140–145
antidiabetiká	(1): 18–22	hypolipidémika	(2): 68–73
antihypertenzívne lieky	(1): 11–17	chronická rana	(2): 98–101
anti-VEGF	(3): 185–188	indikčné obmedzenia	(2): 130–139
AT1-blokátory	(2): 68–73	inhibitory ACE	(2): 68–73
aterogénna dyslipidémia	(2): 140–145	intenzifikovaný inzulínový režim	(2): 122–124
ateroskleróza	(2): 140–145	inzulín lispro mix	(2): 122–124
autonómna neuropatia	(2): 108–116	jednoduchosť a finančná nenáročnosť	(2): 98–101
bazálne analógy inzulínu	(2): 130–139	kardiorenálny syndróm	(1): 31–35
cievy	(2): 90–97	kardiovaskulárne ochorenia	(1): 27–30
cílová hodnota krvného tlaku	(2): 68–73	kardiovaskulárna mortalita	(2): 102–107
časná inzulínová terapie diabetu 2. typu	(3): 165–168	kardiovaskulárny riziko	(3): 165–168
časná kombinačná liečba	(3): 165–168	komorová fibrilácia	(1): 36–40
časná liečba diabetu	(3): 165–168	kompliancia	(1): 11–17
dermoepidermálne štepky	(2): 98–101	komplikácie	(2): 108–116
diabetes mellitus	(1): 18–22	larvoterapia	(2): 74–83
	(1): 23–26	laserová liečba	(3): 176–180
	(1): 27–30	liečba prediabetu	(3): 165–168
	(1): 31–35	liečba pomocou živých bunkových línií	(2): 74–83
	(1): 36–40	liečba riadeným podtlakom	(2): 74–83
	(2): 102–107	mikroalbuminúria	(2): 117–121
	(2): 108–116	mikroalbuminurie	(2): 68–73
	(2): 117–121	multiorgánovomultivaskulárna choroba	(1): 36–40
	(3): 190–192	nefroprotektie	(2): 68–73
diabetes mellitus 1. typu	(3): 185–188	neovaskularizácie terča zrakového nervu	(3): 185–188
diabetes mellitus 2. typu	(2): 122–124	neovaskulárny glaukóm	(3): 190–192
diabetes mellitus-výskyt	(3): 193–199	pars plana vitrektómia	(3): 170–175
diabetická kardiomyopatia	(1): 18–22	periférna neuropatia	(2): 108–116
diabetická nefropatia	(1): 31–35	podiatrické centrum	(2): 102–107
	(2): 117–121	prediabetes	(3): 165–168
	(S1): 1–6	predsieňová fibrilácia	(1): 27–30
diabetická noha	(2): 74–83	premixované inzulínové analógy	(2): 122–124
	(2): 90–97	prevence diabetu	(3): 165–168
	(2): 98–101	primárny glaukóm s otvoreným uhlom	(3): 190–192
diabetická retinopatia	(3): 170–175	ranibizumab	(3): 185–188
	(3): 176–180	rehospitalizácie pre akútne ochorenia	(1): 23–26
	(3): 181–184	rizikové faktory	(2): 84–89
	(3): 193–199	skrining	(3): 176–180
diabetické ulcerace	(2): 102–107	srdcové zlyhávanie	(1): 18–22
diabetický edém makuly	(3): 170–175	syndróm diabetickej nohy	(2): 84–89
	(3): 185–188	tehotenstvo	(3): 181–184
	(3): 193–199	tlak vnútroočný	(3): 190–192
diagnostika diabetickej nefropatie	(2): 117–121	tolerancia	(1): 11–17
dyslipoproteinémia	(2): 140–145	transplantácia autológnych štepov	(2): 98–101
endovaskulárne výkony	(2): 90–97	trvanie účinku	(1): 11–17
etiopatogenéza	(2): 84–89	zobrazovacie metódy	(2): 90–97
glaukóm	(3): 190–192		

Forum diabetologicum 2013; 2

Index of key words

key word	(číslo): strany	key word	(číslo): strany
ACE inhibitors	(2): 68–73		(3): 176–180
acute coronary syndrome	(1): 23–26		(3): 181–184
acute heart failure	(1): 23–26		(3): 193–199
aliskiren	(1): 11–17	diagnosis of diabetic nephropathy	(2): 117–121
angiotensin receptor blockers	(2): 68–73	duration of action	(1): 11–17
antidiabetics	(1): 18–22	dyslipoproteinemia	(2): 140–145
antihypertensive drugs	(1): 11–17	early combination treatment	(3): 165–168
antiplatelet therapy	(2): 68–73	early insulin treatment in type 2 diabetes	(3): 165–168
anti-VEGF	(3): 185–188	early treatment of diabetes	(3): 165–168
atherogenic dyslipidemia	(2): 140–145	endovascular intervention	(2): 90–97
atherosclerosis	(2): 140–145	etiopathogenesis	(2): 84–89
atrial fibrillation	(1): 27–30	forgiveness	(1): 11–17
autonomic neuropathy	(2): 108–116	glaucoma	(3): 190–192
basal insulin analogues	(2): 130–139	gliptines	(2): 130–139
blood vessels	(2): 90–97	goal blood pressure	(2): 68–73
cardiorenal syndrome	(1): 31–35	heart failure	(1): 18–22
cardiovascular disease	(1): 27–30	hypertriglyceridemia	(2): 140–145
cardiovascular mortality	(2): 102–107	chronical wound	(2): 98–101
cardiovascular risk	(3): 165–168	imaging methods	(2): 90–97
compliance	(1): 11–17	indicating restrictions	(2): 130–139
complications	(2): 108–116	insulin lispro mix	(2): 122–124
dermoepidermal skin grafts	(2): 98–101	intensified insulin regimen	(2): 122–124
diabetes mellitus	(1): 18–22	intraocular pressure	(3): 190–192
	(1): 23–26	laser treatment	(3): 176–180
	(1): 27–30	lipid-lowering drugs	(2): 68–73
	(1): 31–35	maggot therapy	(2): 74–83
	(1): 36–40	microalbuminuria	(2): 68–73
	(2): 102–107		(2): 117–121
	(2): 108–116	multiorganomultivascular arterial disease	(1): 36–40
	(2): 117–121	neovascular glaucoma	(3): 190–192
	(3): 190–192	nephroprotection	(2): 68–73
diabetes mellitus type 1	(3): 185–188	optic disc neovascularization	(3): 185–188
diabetes mellitus type 2	(2): 122–124	pars plana vitrektómia	(3): 170–175
diabetes mellitus-incidence	(3): 193–199	peripheral neuropathy	(2): 108–116
diabetes prevention	(3): 165–168	prediabetes	(3): 165–168
diabetic cardiomyopathy	(1): 18–22	prediabetes treatment	(3): 165–168
diabetic foot	(2): 74–83	pregnancy	(3): 176–180
	(2): 90–97		(3): 181–184
	(2): 98–101	premixed insulin analogues	(2): 122–124
diabetic foot clinic	(2): 102–107	primary open-angle glaucoma POAG	(3): 190–192
diabetic foot syndrome	(2): 84–89	ranibizumab	(3): 185–188
diabetic foot ulcer	(2): 102–107	rehospitalization for acute diseases	(1): 23–26
diabetic macular edema	(3): 170–175	risk factors	(2): 84–89
	(3): 185–188	screening	(3): 176–180
	(3): 193–199	simplicity and low cost	(2): 98–101
diabetic nephropathy	(1): 31–35	transplantation of autolog skin grafts	(2): 98–101
	(2): 117–121	treatment with controlled vacuum	(2): 74–83
	(S1): 1–6	treatment with live cell lines	(2): 74–83
diabetic retinopathy	(3): 170–175	ventricular fibrillation	(1): 36–40